Bipartisan Bill Could Open NYSE, Nasdaq to Cannabis Companies
New congressional legislation would allow marijuana businesses to list on major US exchanges, potentially ending the Canadian listing exodus.
A new bipartisan congressional bill aims to eliminate one of the cannabis industry's most persistent capital market barriers by allowing marijuana companies to list directly on major US exchanges including the New York Stock Exchange and Nasdaq. The legislation addresses a longstanding frustration for American cannabis operators who currently face exclusion from premier US trading venues due to federal prohibition.
The proposal represents a targeted approach to cannabis capital markets reform, focusing specifically on exchange access rather than broader banking or tax issues. This narrow scope could improve its chances of passage compared to comprehensive reform packages that have stalled in Congress. For investors, exchange access would dramatically improve liquidity and institutional participation in cannabis stocks, which currently trade primarily on over-the-counter markets or Canadian exchanges.
Major US multi-state operators like Curaleaf, Trulieve, and Green Thumb Industries currently list on the Canadian Securities Exchange or trade as pink sheet stocks in the US, limiting their investor base and creating pricing inefficiencies. Direct listing on NYSE or Nasdaq would likely trigger significant institutional buying, as many funds are prohibited from investing in OTC securities. The enhanced visibility and credibility of major exchange listings could also reduce the valuation discount that US cannabis companies trade at compared to their Canadian counterparts.
The timing coincides with renewed momentum around federal cannabis reform, including ongoing discussions about rescheduling marijuana from Schedule I. However, this legislation could advance independently of broader reform efforts, potentially providing immediate relief for an industry that has seen market capitalizations compress significantly over the past two years. Cannabis companies have collectively lost billions in market value since 2021 peaks, partly due to limited access to traditional capital markets.
If enacted, the bill would likely accelerate consolidation within the fragmented US cannabis market, as exchange-listed companies would gain easier access to equity capital for acquisitions. The legislation also positions US exchanges to capture cannabis trading volume that has migrated to Toronto, potentially bringing billions in market capitalization back to American markets. For the broader cannabis sector, exchange access represents a critical step toward normalization and could attract the institutional capital needed to fund expansion as state markets continue to mature.